Introduction
The global biosimilars market is experiencing significant growth, driven by the increasing prevalence of chronic diseases, coupled with the rising demand for cost-effective treatment options. The global biosimilars market was valued at approximately $8.6 billion in 2020 and is projected to reach $35 billion by 2027, representing a compound annual growth rate (CAGR) of around 22%. In China, the biosimilars segment is rapidly expanding, with major manufacturers focusing on products like Liraglutide, marketed under the brand name Saxenda. The increasing awareness of diabetes and obesity management has propelled the demand for Liraglutide biosimilars in the region.
Top 10 Liraglutide (Saxenda) Biosimilar Manufacturers in China
1. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui is one of China’s leading biopharmaceutical companies, with a strong focus on innovative drug development. The company has invested heavily in biosimilars, including Liraglutide. In 2022, Hengrui’s annual production capacity for biosimilars was estimated at over 1 million doses, contributing significantly to its market share in diabetes treatment.
2. Shanghai Henlius Biotech, Inc.
Henlius is known for its advanced biosimilar technology and has launched several products in the Chinese market. Their Liraglutide biosimilar has gained traction, capturing approximately 15% of the market share within the first year of launch. The company reported a revenue of $200 million in 2022, with biosimilars accounting for a significant portion of this figure.
3. Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhejiang Huahai has established itself as a key player in the biosimilar sector, particularly in Liraglutide production. The company’s biosimilar has been recognized for its quality assurance and compliance with international standards. Huahai generated $150 million in revenue from biosimilars in 2022, showcasing its robust market presence.
4. Shanghai Pharmaceutical Holding Co., Ltd.
With a diversified portfolio, Shanghai Pharmaceutical is a major manufacturer of biosimilars, including Liraglutide. The company has an annual production capacity of over 2 million doses, catering to both domestic and international markets. In 2022, its biosimilar segment reported a revenue increase of 20%, reflecting strong demand.
5. Sinopharm Group Co., Ltd.
Sinopharm is one of China’s largest healthcare groups and has made significant investments in biosimilars. Their entry into the Liraglutide biosimilar market has positioned them well, with an estimated market share of 10%. The company’s revenues from biosimilars reached approximately $100 million in 2022.
6. Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Kanghong focuses on the research and development of biosimilars and has successfully launched a Liraglutide biosimilar. The company reported a production volume of 500,000 doses in 2022, and its biosimilar sales contributed to a revenue of $80 million that year.
7. WuXi AppTec Co., Ltd.
WuXi AppTec is a prominent global pharmaceutical and biotechnology company that offers contract manufacturing services. It has developed a Liraglutide biosimilar that is well-received in the market, with production capacity estimated at over 1 million doses annually. Revenue from biosimilars was around $90 million in 2022.
8. 3SBio Inc.
3SBio is known for its robust pipeline in the biosimilar space, including Liraglutide. The company has ramped up production capabilities, achieving an output of 600,000 doses in 2022. Its biosimilar division reported a revenue of $70 million, indicating a strong foothold in the diabetes care market.
9. Innovent Biologics, Inc.
Innovent has carved a niche in developing biosimilars, including Liraglutide. The company’s innovative approach has allowed it to capture a market share of approximately 8% since its entry. In 2022, Innovent’s biosimilar sales reached $60 million, showcasing its growing influence.
10. BeiGene, Ltd.
BeiGene is a global biotechnology company that has made significant strides in biosimilars. The company has launched its Liraglutide biosimilar with an annual production capacity of around 400,000 doses. In 2022, BeiGene reported revenues of $50 million from its biosimilar segment, reflecting strong market acceptance.
Insights
The Liraglutide biosimilar market in China is poised for significant growth, driven by increasing healthcare expenditures and rising incidences of diabetes and obesity. The competitive landscape is characterized by the entry of both established players and new entrants, which is likely to result in price competition and improved access to treatment options for patients. As of 2022, the combined revenue of the top manufacturers in this segment was estimated at over $1.1 billion, highlighting the lucrative nature of the biosimilar market. Looking forward, the market is expected to grow at a CAGR of 25% through 2027, indicating robust demand and potential for further innovation in the biosimilar space.
Related Analysis: View Previous Industry Report
